Clinical Application of Genetic Sequencing of Early Gastric Cancer and Gastric Adenoma Patients

Recruiting now

Conditions studied: Early Gastric Cancer, Gastric Adenoma

In brief

Because advanced gastric cancer shows poor prognosis, it is important to detect early gastric cancer or precancerous gastric adenoma patients who have a cure rate of 95% or more. Moreover, a large part of early gastric cancer can be completely resected by endoscopic resection, thus ensuring a very high quality of life for patients. However, there are currently no markers that can be used for diagnosis of early gastric cancer or gastric adenoma. In addition, the biggest problem after endoscopic resection of early gastric cancer is metachronous recurrence of the cancer, which requires repeated endoscopic resection or additional surgical gastrectomy. However, there are no discovered markers for prediction of recurrence. Liquid biopsy is a method of obtaining body fluids such as gastric juice or effusion through an endoscopic inlet during gastroscopy or colonoscopy and blood. Based on the advanced analysis method, liquid biopsy reveals more genetic information than tissue biopsy. Therefore, it is highly likely to become an essential factor in future personalized medicine. Therefore, this study was designed to identify whether tumor's molercular profiling based on tissue or blood could be used for prediction of prognosis and diagnosis of early gastric cancer and precancerous gastric adenoma.

Key facts

Study ID

NCT04665687

Run by

Samsung Medical Center

People needed

1730

Starts

2020-12-17

Expected to finish

2031-12-31

Last updated by the study team

2025-09-12

Who can join

Age: 19 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Those who are over the age of 19
• Those who were histologically confirmed with early gastric cancer or precancerous gastric adenoma
• Patients with early gastric cancer or precancerous gastric adenoma falling under the above criteria who have excess tissue stored from previous non-research purpose biopsy/endodoscopic removal for treatment and diagnosis
• Those whose life expectancy is more than 3 months
• Those who have voluntarily consented to participate in this clinical trial

You may not qualify if…

• Those who will not yield enough samples
• Those who are considered inappropriate for this study in the discretion of the researchers

Where it is running

• Samsung medical center — Seoul, South Korea (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.